BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35472093)

  • 21. Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014.
    Flagg EW; Torrone EA
    Am J Public Health; 2018 Jan; 108(1):112-119. PubMed ID: 29161070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
    J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence, Persistence, Clearance, and Correlates of Genital Human Papillomavirus Infection and Anogenital Warts in a Cohort of Men Living With Human Immunodeficiency Virus in South Africa.
    Chikandiwa A; Pisa PT; Muller EE; Tamalet C; Mayaud P; Chersich MF; Delany-Moretlwe S
    Sex Transm Dis; 2019 May; 46(5):347-353. PubMed ID: 30985636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of HPV vaccination on anogenital warts and respiratory papillomatosis.
    Wangu Z; Hsu KK
    Hum Vaccin Immunother; 2016 Jun; 12(6):1357-62. PubMed ID: 27217191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
    Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Annual prevalence and economic burden of genital warts in Korea: Health Insurance Review and Assessment (HIRA) service data from 2007 to 2015.
    Park YJ; Kim JM; Lee BR; Kim TH; Lee EG
    Epidemiol Infect; 2018 Jan; 146(2):177-186. PubMed ID: 29235433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data.
    Thöne K; Horn J; Mikolajczyk R
    BMC Infect Dis; 2017 Aug; 17(1):564. PubMed ID: 28806926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.
    Donovan B; Franklin N; Guy R; Grulich AE; Regan DG; Ali H; Wand H; Fairley CK
    Lancet Infect Dis; 2011 Jan; 11(1):39-44. PubMed ID: 21067976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure.
    Lurie S; Mizrachi Y; Chodick G; Katz R; Schejter E
    Gynecol Oncol; 2017 Aug; 146(2):299-304. PubMed ID: 28602548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of anogenital warts in Germany: a population-based cohort study.
    Kraut AA; Schink T; Schulze-Rath R; Mikolajczyk RT; Garbe E
    BMC Infect Dis; 2010 Dec; 10():360. PubMed ID: 21182757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The incidence of genital warts in Australian women prior to the national vaccination program.
    Brotherton JM; Heywood A; Heley S
    Sex Health; 2009 Sep; 6(3):178-84. PubMed ID: 19653953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.
    Leval A; Herweijer E; Ploner A; Eloranta S; Fridman Simard J; Dillner J; Young C; Netterlid E; Sparén P; Arnheim-Dahlström L
    J Natl Cancer Inst; 2013 Apr; 105(7):469-74. PubMed ID: 23486550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
    Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
    BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
    JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation.
    Drolet M; Laprise JF; Brotherton JML; Donovan B; Fairley CK; Ali H; Bénard É; Martin D; Brisson M
    J Infect Dis; 2017 Dec; 216(10):1205-1209. PubMed ID: 28968800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.
    Marty R; Roze S; Bresse X; Largeron N; Smith-Palmer J
    BMC Cancer; 2013 Jan; 13():10. PubMed ID: 23298365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006-2014: The impact of human papillomavirus vaccination.
    Shing JZ; Hull PC; Zhu Y; Gargano JW; Markowitz LE; Cleveland AA; Pemmaraju M; Park IU; Whitney E; Mitchel EF; Griffin MR
    Papillomavirus Res; 2019 Jun; 7():141-149. PubMed ID: 30980966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada.
    Kliewer EV; Demers AA; Elliott L; Lotocki R; Butler JR; Brisson M
    Sex Transm Dis; 2009 Jun; 36(6):380-6. PubMed ID: 19556932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services.
    Oliphant J; Perkins N
    N Z Med J; 2011 Jul; 124(1339):51-8. PubMed ID: 21952330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 9-Valent human papillomavirus vaccine: a review of the clinical development program.
    Luxembourg A; Moeller E
    Expert Rev Vaccines; 2017 Nov; 16(11):1119-1139. PubMed ID: 28956458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.